Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Psychiatry/Psychology

Search Medical Condition
Please enter condition
Please choose location

Manic Disorders Clinical Trials

A listing of Manic Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (23) clinical trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIXED-DOSE CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH BIPOLAR I DEPRESSION

Phase

A phase 4 unequal randomization, double blind study to evaluate the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an Open label and long term maintenance treatment in children and adolescents aged 10-17 years diagnosed with acute manic or mixed Bipolar I Disorde

Phase N/A

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

Participants will be randomized to receive double-blind suvorexant or placebo for one week, after which all participants will receive open treatment with suvorexant for three months.

Phase

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

The primary objective of this study is to evaluate under double blind conditions the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an open label and long term maintenance treatment on extended release Equetro in children and adolescents aged 10-17 year diagnosed with acute manic ...

Phase

Asenapine for Bipolar Depression

86 patients with an episode of major depression associated with bipolar disorder, type I will be recruited by two sites for the study over fifteen months. Medication will be administered in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at 5 mg bid. Dose may ...

Phase

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.

Phase